Enzo Biochem at Bio-Europe 2009 (NYSE:ENZ)
Source: http://feedproxy.google.com/~r/FavStocks/~3/Z5UjsJAZ54c/Posted on Thursday, November 5th, 2009 | In Biotech, Investing Lessons, Stocks to Watch
Speaking at the Bio-Europe 2009 Conference in Austria, Enzo Biochem, Inc (NYSE:ENZ) announced that the Company’s therapeutic platforms are utilizing oral immune regulation for immune mediated diseases. The Company further said that the oral immune regulation platform is a bright area of therapeutic promise. Currently, the Company’s therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicine for uveitis and Crohn’s disease and is conducting pre-clinical research on several candidate compounds that are aimed at producing new mineral and organic bone, including therapies for osteoporosis and fractures and other applications.
The Company announced that their therapeutics subsidiary has long viewed oral immune regulation as a promising platform and that they continue to pursue this platform through studies that involve treatment candidates of unmet medical needs. Enzo Biochem’s Vice President for Corporate Development, David Goldberg, mentioned that as they are growing their Life Sciences and Clinical Labs division they are also utlizing the experience and knowledge gained in drug discovery programs to better the position of Enzo Biochem in the rapidly growing companion diagnostics space. He further stated that the Company has made progress in the development of its drug screening platform that has yielded orally delivered small molecules having potential effects for bone disorders and diabetes.
Enzo Biochem looks after the research and development, manufacturing and licensing of innovative healthcare products and technologies based on molecular biology and genetic engineering and in providing diagnostic services to the medical community. The Company currently has two ongoing clinical studies. Alequal is an individualized therapy for the treatment of Crohn’s disease and is a Phase 2 clinical trial with no treatment side effects. Optiquel is an oral novel peptide designed to inhibit progression of autoimmune aveitis.
Last 5 posts by Jay Garcilazo
- Dyax approaching its PDUFA Date (DYAX) - November 24th, 2009
- FDA Decision scheduled for Santarus (SNTS) - November 23rd, 2009
- FDA Decision scheduled for Santarus (SNTS) - November 23rd, 2009
- CytRx Technical Breakout on Pending News (NASDAQ:CYTR) - November 23rd, 2009
- CytRx Technical Breakout on Pending News (NASDAQ:CYTR) - November 23rd, 2009
 About Jay Garcilazo (http://favstocks.com)
I grew up in Boca Raton, Florida. After graduating high school I enrolled at Florida State University where I studied Journalism and Political Science. It was around this time that I got a job in the healthcare industry, a job that would give me a lot of experience as I worked and moved up over the next four and a half years. This along with working for a hedge fund manager for years, were the greatest learning experiences of my life so far. I have also been fortunate enough to have lived all over the country in, Austin, Texas, Queens, New York, Great Falls, Montana, Cleveland, Ohio, Chattanooga, Tennessee, Atlanta, Georgia, and all over the state of Florida. As well as living in many places I have traveled all over, been to all of the states except California (Had a layover at LAX once but I don’t think that counts), Oregon, and Hawaii. Traveled most of the Caribbean, I have also been to many destinations in Canada, and Mexico. I even did a stint through Europe. As well as traveling and living all over I have also worked in a great many industries. I have been employed in finance, healthcare, title, mortgage, travel, video game development, hospitality, and news industries. Besides working for an investment company I have also done quite a bit of investing on my own, and through trial and error, learning from mistakes, and watching the news very closely I have made some decent money for myself. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.